Clinical Trial Update: Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC). [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for atezolizumab in immunotherapy-naive patients with urinary tract squamous cell carcinoma (UTSCC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Urinary Tract
• Urinary Tract Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: University Hospital Southampton NHS Foundation Trust | Conditions: Squamous Cell Carcinoma, Urinary Tract Cancer | Phase 2 | Status: UNKNOWN